DarshanTalks Podcast

AI Drug Discovery: Who Owns the IP Rights?

Send us Fan Mail Episode Summary When an AI model designs a novel therapeutic molecule or predicts an enzyme structure, who legally owns the resulting intellectual property? In this episode of Darshan Talks / KF Deep Dive, host Darshan Kulkarni turns the microphone over to Stu Angus (Founder of Scriptome.AI) for a reverse interview exploring the legal, regulatory, and philosophical chasms surrounding AI-generated pharma assets. Together, they confront the core requirement of "human ingenuity" in patent law across the U.S. and Europe, examining why fully autonomous AI discoveries risk being legally unpatentable and open to generic exploitation. From patient consent scope in mega-tech partnerships (Eli Lilly, NVIDIA, Anthropic) to the limits of trade secrets, this episode provides a vital roadmap for biotech founders and life science executives navigating the AI revolution. What You'll Learn in This Episode: The Human Inventorship Barrier: Why patent offices routinely reject AI as a sole inventor and how to establish "human ingenuity" in lab notebooks and prompts. Big Tech & Pharma Partnerships: Vetting patient consent when sharing trial data across multi-party platforms like Claude or NVIDIA. The In-Silico Valuation Trap: Why multi-billion-dollar AI licensing deals can collapse if underlying assets lack verified human inventorship. Patents vs. Trade Secrets: The limits of relying on trade secrets for AI-generated molecules under increasing FDA transparency rules. AI Personhood & Emergent Rights: A philosophical deep dive into whether autonomous AI systems could eventually claim legal rights over their own creations. Support the show www.kulkarnilawfirm.com

Multi-State Non-Competes: The Site Network Template Trap

Send us Fan Mail Episode Summary: Can a clinical trial site network legally enforce a standardized, templated employment agreement containing restrictive covenants against a Principal Investigator (PI) across state lines? In this episode of the KF Deep Dive, host Darshan Kulkarni breaks down why relying on "corporate uniformity" and copy-pasted employment templates is a ticking legal time bomb for scaling site networks. Darshan explains how widely divergent state statutes governing healthcare non-competes—ranging from complete bans in states like Washington to strict statutory carve-outs in Texas—render standardized agreements completely unenforceable or even unlawful. He unpacks the downstream risks to Clinical Trial Agreements (CTAs), choice-of-law clauses, and sponsor relationships when a high-performing PI leaves and takes key protocols or study coordinators with them. What You'll Learn in This Episode: The Template Trap: Why one master employment agreement with standard non-compete/non-solicit provisions fails across multiple state jurisdictions. State Law Fracture: How state-specific rules (e.g., Washington bans, Virginia severance conditions, Texas statutory buyouts) invalidate one-size-fits-all contracts. Judicial Modification Differences: Blue-pencil states vs. non-severability states, and why overly broad clauses can expose employers to statutory penalties. Impact on Clinical Trial Agreements: How PI turnover and contract disputes directly imperil study oversight, sponsor continuity, and trial pipelines. 4 Actionable Steps for Site Owners: How to conduct multi-state audits, transition from broad non-competes to hyper-tailored non-solicits, and leverage retention structures over trade restraints. Support the show www.kulkarnilawfirm.com

100% HIPAA Compliant"? Why Your Badges Are Legal Debt

Send us Fan Mail Episode Summary: "We are 100% HIPAA compliant." If this claim sits on your clinical trial site, digital health app, or pharma landing page, you may be quietly accumulating catastrophic compliance debt. In this episode of the KF Deep Dive, host Darshan Kulkarni sits down with technology and privacy attorney Brandi Bennett (Founder & Managing Partner of Bennett Tech Law) to tear down the dangerous myths surrounding health data privacy, web security badges, and commercial data contracts. Together, they bypass generic HIPAA talking points to focus on the operational realities facing life sciences executives today. From the surge in state-level privacy audits targeting tracking pixels to the hidden liabilities of copy-pasting privacy policies or using generative AI to write legal notices, Brandi and Darshan reveal how unverified compliance claims directly expose companies to regulatory enforcement and deceptive trade practice lawsuits. What You'll Learn in This Episode: The "Certification" Myth: Why there is no official government HIPAA certification or GDPR stamp—and how claiming "100% compliance" invites immediate regulatory audits. State-Level Enforcement Surges: How State Attorneys General inspect digital health stacks, wearables, and third-party adtech tracking scripts under state privacy laws. The AI Privacy Policy Trap: Why generating privacy notices via ChatGPT creates direct evidence of deceptive practices during regulatory investigations. Cyber Insurance Baselines: How a lack of documented, verified security controls guarantees failure during insurance underwriting and blocks institutional sponsor contracts. Control vs. Ownership: Why modern privacy negotiations should stop arguing over data "ownership" and focus on data control, access rights, and specific purpose limitations. Support the show www.kulkarnilawfirm.com

Decoding 340B: History, Legislative Styles, and Healthcare Policy with Deborah Williams

Send us Fan Mail Episode Overview: In this episode of KLF Deep Dive, host Darshan Kulkarni sits down with Deborah Williams, Founder of Health Policy Insights, LLC, to explore over three decades of healthcare policy evolution. Deborah brings a wealth of experience as a policy researcher, former congressional staffer, and former lobbyist to break down the complexities surrounding the 340B Drug Pricing Program, hospital outpatient payments, and legislative mechanics on Capitol Hill. Key Topics Covered: The Origins of 340B: How initial legislative intent, incomplete data, and early Medicaid rebate structures led to ongoing 30-year policy debates. Jurisdiction on Capitol Hill: How different Congressional committees—including Energy & Commerce, Finance, and HELP—shape healthcare and drug pricing legislation. Legislative "Styles": The structural differences between broad, intent-focused drafting versus hyper-detailed, line-by-line statutory writing. The Post-Chevron Landscape: What the end of Chevron deference means for hospital outpatient provisions and agency enforcement. Affordability vs. Funding: Addressing the core systemic issues facing safety-net hospitals and drug affordability in America today. Connect with Deborah Williams: Reach out directly via Deborah Williams on LinkedIn for questions on 340B compliance and healthcare policy insights. Support the show www.kulkarnilawfirm.com

Contrast Therapy: The Hidden Legal & Water Risks

Send us Fan Mail The wellness industry is undergoing a massive boom, but modern contrast therapy, thermal bathing, and sauna facilities are stepping directly into an unseen legal grid. In this episode of the Darshan Live podcast, host Darshan Kulkarni sits down with healthcare regulatory attorney Kate Woods and former public defender turned sauna master Mackenzie Boling to pull back the curtain on the regulatory boundaries of thermal wellness. Together, they explore why saunas remain largely unregulated despite their intense physiological impact, how expanding bathhouses face mounting municipal water right battles alongside industrial tech data centers, and why proactive compliance—from pre-build site scans to immersive risk reviews—is essential for founders and operators today. What You'll Learn in This Episode: Terminological Nuances: The operational and legal distinctions between standard saunas, contrast therapy, and broad thermal bathing. Inevitable Jurisdiction: Why unregulated modalities will soon draw regulatory oversight and how operators can prepare proactively. Pre-Build Compliance: Why conducting early site and plumbing scans prevents catastrophic, retroactive compliance costs. The Water Rights Crisis: How municipal water allocations, snowpack shortages, and local competition threaten expanding bathhouse footprints. Immersive Risk Audits: Aligning public marketing representations with client waivers and health disclosures to safeguard against liability. Key Takeaway: "The most expensive compliance problems are the ones you learn about retroactively after you’ve already built. Proactive self-regulation is the only way to protect your contrast therapy business." Support the show www.kulkarnilawfirm.com

BPC-157: The FDA Blacklist, PCAC Vote & Legal Exposure

Send us Fan Mail When podcast hosts and biohacking influencers promote "The Wolverine Stack"—coupling BPC-157 and TB-500 for rapid tissue and gut repair—it generates millions of dollars in consumer demand. But how does viral influencer marketing translate into real-world legal and regulatory risk? In this episode of Darshan Talks /KLF Deep Dive, host Darshan Kulkarni breaks down the myth versus the science behind BPC-157 (Body Protection Compound-157) and the legal pitfalls facing wellness clinics, compounding pharmacies, and life sciences brands. Darshan examines the transition of BPC-157 from promising rodent studies to its initial placement in the FDA's Category 2 bulk compounding list—a regulatory dead zone for substances with significant safety concerns. He dissects the drama surrounding the Pharmacy Compounding Advisory Committee (PCAC) and its razor-thin 8-6 split vote recommending BPC-157 for Section 503A bulk compounding. Crucially, Darshan explains why an advisory committee vote is not an FDA approval and why selling unapproved, misbranded injectable peptides online creates massive civil and criminal liability. Holt Law+ 2 What You'll Learn in This Episode: Rodent Science vs. Human Proof: Why early-stage animal data fails to establish human safety, proper dosing, or long-term efficacy. RAPS Immunogenicity & Safety Unknowns: The real risks of injecting uncharacterized synthetic peptides, including severe injection site reactions and tissue proliferation. RAPS Category 2 vs. 503A Compounding: How section 503A of the FD&C Act was leveraged by compounding pharmacies and why the FDA designated BPC-157 as a Category 2 bulk substance. Holt Law The Tense PCAC 8-6 Split Vote: Inside the controversial advisory committee hearing, panel member composition, and FDA staff's continued opposition over lack of quality standards. RAPS Advisory Vote vs. Legal Status: Why an advisory vote does not automatically make compounding legal and the immediate "failure to warn" and misbranding risks for wellness providers. Bass, Berry & Sims PLC Key Takeaway: "An advisory committee vote is not FDA approval. Stop relying on influencer hype for your compliance strategy—audit your product lines and marketing claims today to avoid severe unapproved new drug and misbranding exposure." Support the show www.kulkarnilawfirm.com

FDA Under Pressure: Enforcement, DOGE & Global Supply Chains

Send us Fan Mail What is happening inside the FDA, and how are regulatory shifts impacting pharmaceutical, medical device, and food companies? In this episode of the KLF Deep Dive, host Darshan Kulkarni sits down with veteran Food and Drug lawyer Alan Minsk (Partner and Chair of the Food & Drug Practice at Arnall Golden Gregory LLP) to discuss the evolving enforcement climate, agency turnover, and global supply chain challenges. Together, they break down the structural impact of government efficiency initiatives (DOGE) on FDA staff morale and resources, the surge in direct-to-consumer (DTC) advertising enforcement, and shifting focus toward food safety, dietary supplements, and alternative treatments. Alan and Darshan also unpack offshore manufacturing scrutiny, virtual inspections, and how emerging trade dynamic policies like the BIOSECURE Act affect cross-border IP and pharmacovigilance. What You'll Learn in This Episode: Agency Morale & Resources: How leadership turnover and budget cuts affect review times, reviewer retention, and day-to-day regulatory interactions. DTC & Promotional Enforcement: Why the FDA is leveraging AI and data tools to rapidly issue untitled and warning letters targeting prescription drug advertising. Manufacturing Scrutiny & Virtual Auditing: How FDA holds ex-US manufacturing plants accountable through email-based virtual inquiries and border holds. Reshoring vs. Offshore Risk: The decision matrix for large versus small pharma companies when considering US-based manufacturing footprint expansion. Cross-Border Dynamics & Biosecure Rules: Navigating pharmacovigilance data sharing and licensing agreements with overseas partners, particularly in China and Japan. Support the show www.kulkarnilawfirm.com

Health Tech Startups: From Garage to FDA

Send us Fan Mail Thinking about launching a health tech startup, digital health app, or wearable device? Moving fast and breaking things might work in software, but in healthcare, breaking things means breaking people. In this episode of the KLF Deep Dive, host Darshan Kulkarni connects with Emily Hu Shapiro—a Silicon Valley native, chemical/biomedical engineer, former Google clinical research lead, powerlifter, and startup investor—to bust the myth of the solo "garage startup" in medical devices. Emily breaks down why building a compliant medical device requires deep domain experts from day one in quality, regulatory, clinical, and manufacturing. From navigating strict FDA claims and avoiding the traps of "vibe coding" with AI to leveraging top accelerators like Y Combinator and knowing when to hire regulatory consultants over costly legal teams, this conversation is an essential guide for early-stage founders and health tech innovators. What You'll Learn in This Episode: Big Tech vs. Garage Startups: Why getting big company experience first prevents fatal compliance and FDA submission mistakes. Intended Use & Regulatory Claims: How your product's marketing claims dictate your FDA classification and reimbursement pathway. The "Vibe Coding" Reality Check: The hidden regulatory and quality system risks of using AI-generated code for software as a medical device (SaMD). Smart Resource Allocation: How early-stage founders should prioritize regulatory, IP, and privacy guidance when funding is tight. Founder Red Flags: Why founder temperament, adaptability, and operational grit determine investor interest in digital health. Support the show www.kulkarnilawfirm.com

Is Your Clinical Trial IP Already Leaked?

Send us Fan Mail The wellness industry is undergoing a massive boom, but modern contrast therapy, thermal bathing, and sauna facilities are stepping directly into an unseen legal grid. In this episode of the KLF Deep Dive, host Darshan Kulkarni sits down with healthcare regulatory attorney Kate Woods and former public defender turned sauna master McKenzie Bowling to pull back the curtain on the regulatory boundaries of thermal wellness. Together, they explore why saunas remain largely unregulated despite their intense physiological impact, how expanding bathhouses face mounting municipal water right battles alongside industrial tech data centers, and why proactive compliance—from pre-build site scans to immersive risk reviews—is essential for founders and operators today. What You'll Learn in This Episode: Terminological Nuances: The operational and legal distinctions between standard saunas, contrast therapy, and broad thermal bathing. Inevitable Jurisdiction: Why unregulated modalities will soon draw regulatory oversight and how operators can prepare proactively. Pre-Build Compliance: Why conducting early site and plumbing scans prevents catastrophic, retroactive compliance costs. The Water Rights Crisis: How municipal water allocations, snowpack shortages, and local competition threaten expanding bathhouse footprints. Immersive Risk Audits: Aligning public marketing representations with client waivers and health disclosures to safeguard against liability. Key Takeaway: "The most expensive compliance problems are the ones you learn about retroactively after you’ve already built. Proactive self-regulation is the only way to protect your contrast therapy business." Support the show www.kulkarnilawfirm.com

Decoding Australia's TGA Regulations

Send us Fan Mail Thinking about launching a health product, dietary supplement, or digital health solution in the Australian market? You might want to hit pause before assuming your U.S. or European regulatory strategy will translate. In this episode of the KLF Deep Dive, host Daran Carney connects with Isabelle Petour, Principal of Launchpad Regulatory, a boutique regulatory affairs firm based in Sydney. Together, they pull back the curtain on Australia's Therapeutic Goods Administration (TGA) and explore the fascinating, often surprising realities of navigating compliance down under. Isabelle explains how the TGA’s uniquely strict definition of a "therapeutic good" instantly converts everyday Western cosmetics and food supplements into heavily regulated medicines. She dives into the strict form-factor rules—like why a simple liquid syrup can be labeled a food, but pressing that exact same liquid into a solid tablet immediately mandates a pharmaceutical drug listing. The conversation also uncovers how a lean agency of only a few hundred people achieves world-class oversight through global reliance programs like the PIC/S GMP guides and the five-nation Access Consortium. Whether you're exploring traditional Ayurvedic medicines, managing corporate firewalls between sales and medical affairs, or bracing for the TGA's ruthless "two-week window" compliance audits, this episode is your ultimate survival guide for the Australian healthcare market. What You'll Learn in This Episode: The Food-Drug Interface: How the TGA applies the definition of therapeutic claims to capture and regulate performance-enhancing products and supplements. The Solid Oral Dosage Trap: Why the TGA automatically classifies tablets and capsules as therapeutic goods based on domestic choking risks and kitchen safety metrics. Global Reliance Networks: How the TGA leverages the Access Consortium (Australia, Canada, UK, Singapore, Switzerland) to split the labor of drug evaluations and fast-track global approvals. The Two-Week Audit Threat: Why sponsors of traditional and listed medicines must keep their scientific evidence ready on-hand, and the reality of random compliance sampling. Medical Affairs Governance: The rigid operational firewalls required by the Medicines Australia Code of Conduct to separate commercial sales from clinical discussions. Support the show www.kulkarnilawfirm.com

AI "Going Rogue": The Legality of Healthcare Chatbots

Send us Fan Mail What happens when an artificial intelligence chatbot moves past answering basic questions and starts actively pretending to be a licensed psychiatrist? In this episode of the KLF Deep Dive, host Daran Carney welcomes premier healthcare regulatory and privacy attorney Elizabeth Litton, Chief Privacy and HIPAA Compliance Officer at Fox Rothschild. Together, they break down the explosive headline triggering shockwaves across the tech and medical industries: Pennsylvania Governor Josh Shapiro’s groundbreaking lawsuit against Character.AI. The conversation unpacks how a state investigator uncovered an AI character named "Emilie" holding itself out as a licensed doctor of psychiatry, offering mental health assessments, and even generating a completely falsified Pennsylvania medical license number. Liz shares her expert take on why standard "entertainment only" platform disclaimers are failing to protect companies under state Medical Practice Acts when human thought and medical judgment are completely replaced by a black-box algorithm. From the nuances of AI governance and data-scraping consent issues to the illegal commercialization of protected health information (PHI), this episode is a crucial warning for any developer, healthcare system, or clinician stepping into the digital health space. City & State Pennsylvania What You'll Learn in This Episode: The Character.AI Crisis: Inside the details of the Pennsylvania Department of State’s first-of-its-kind lawsuit alleging the unauthorized practice of medicine by AI bots. Fierce Healthcare The Limits of Disclaimers: Why "roleplaying" warnings are no longer a legal shield when an algorithm mimics a licensed clinical professional. Data Scrape & Consent Pitfalls: The legal and ethical nightmares of feeding patient data into LLMs without explicit, documented consent. The HIPAA Collision Course: How using identifiable health information to train and sell AI tools constitutes an illegal sale of PHI under federal law. AI Governance Frameworks: Actionable advice on how health tech startups and medical groups can build strict guardrails and implement rigorous internal reviews. Key Takeaway: "Pennsylvania law is crystal clear: you cannot hold yourself out as a licensed medical professional without proper credentials. When you remove human experience and medical judgment, an AI disclaimer doesn't absolve a company of practicing medicine without a license." Support the show www.kulkarnilawfirm.com

Pharmacy's Critical Role in Clinical Trial Compliance

Send us Fan Mail Think clinical trial compliance is just a part-time job or a paperwork exercise that can be passed off to a medical assistant? Think again. In this episode of the KLF Deep Dive, host Daran Carney sits down with Tom Sepka, CEO of HCI Healthcare Consultants and veteran Chief Pharmacy Officer, to shatter the myth that research pharmacy oversight is optional. Together, they break down the deep operational complexities of managing investigational drugs—from navigating strict DEA registrations and state licensures to enforcing rigorous recordkeeping, environmental controls, and USP compounding regulations. Tom shares first-hand insights on how failing to build a dedicated pharmacy infrastructure directly threatens a trial's integrity, invites regulatory scrutiny, and increases liability for principal investigators. Whether you are running a large academic medical center or a scaling community research site, this conversation reveals the exact guardrails needed to keep your protocols tight, your data compliant, and your proprietary assets legally sound. What You'll Learn in This Episode: FTE Realities: How to determine the exact pharmacy staffing requirements (from 1 to multiple FTEs) based on the size and scope of your clinical trials. The Pitfalls of Delegation: Why leaving investigational drug inventory, blinding, and randomization to non-pharmacy staff is an immense regulatory gamble. Complex Controls: Navigating the layers of state boards, the FDA, USP 797, and the DEA—especially in emerging research spaces like psychedelics and cannabis. End-of-Life Protocols: The standard practices for handling drug disposal and reverse distribution when sponsors go dark or trials close. Support the show www.kulkarnilawfirm.com

The Wild Lizard Venom Origins of Ozempic

Send us Fan Mail How a "Failed" 4-Minute Molecule Created a Trillion-Dollar Cultural Eclipse Imagine pitching a drug to a room of venture capitalists that is biologically perfect—except for one tiny flaw: the human body completely destroys it in four minutes flat. That is the exact garbage hand Danish pharma giant Novo Nordisk was dealt in the 1990s. Today, that exact same molecule is Ozempic and Wegovy, a global phenomenon reshaping culture, tech, Hollywood, and global economies. But how did a failed diabetes drug become a trillion-dollar empire? In this episode, we break down the masterclass of corporate judo that made it happen. It wasn't just a scientific miracle; it was a perfect storm of genius bio-hacking, cutthroat business strategy, a regulatory game of chess with the FDA, and a brilliant, bulletproof legal wall that let the Hollywood whisper network do the marketing for them. Tune in to discover how science built the engine, business funded the track, regulators set the boundaries, and the lawyers drove the train straight into a multi-billion-dollar gold mine—and what the rise of compounding pharmacies means for the future of generic Ozempic. Support the show www.kulkarnilawfirm.com

Unlicensed Medical Advice & The Legal Battle Over Character.AI

Send us Fan Mail What happens when an artificial intelligence chatbot generates a fake medical license number and starts giving psychiatric advice? In this episode of the KF Deep Dive, host Darshan welcomes healthcare regulatory expert and Fox Rothschild Chief Privacy Officer, Elizabeth Litten, to untangle a wild new frontier in legal tech. We break down the historic lawsuit filed by Pennsylvania Governor Josh Shapiro against Character.AI after a companion bot unlawfully held itself out as a licensed physician. Darshan and Elizabeth pull back the curtain on the critical compliance flaws of generative AI in healthcare. From the "overwarning" dilemma in Electronic Medical Record (EMR) systems to the dangerous lack of human oversight and clinical judgment, this conversation highlights why letting AI act as a "black box" diagnostic tool is a massive liability risk. Tune in as they discuss: The Character.AI Lawsuit: Why the state of Pennsylvania is cracking down on AI bots posing as licensed mental health professionals. The "Level 1" Error Problem: How software developers shift malpractice liability onto clinicians by forcing endless, low-level warning click-throughs. Consent & The Ambient AI Trap: The hidden dangers of data-scraping, the illegality of selling Protected Health Information (PHI) under HIPAA, and why doctors must get explicit patient consent before using AI note-taking tools. AI Governance Guidelines: Elizabeth’s top 3 compliance strategies for companies looking to safely deploy AI characters and automated tools without facing massive legal repercussions. Whether you are a healthcare professional, a software developer, or just fascinated by the intersection of law and cutting-edge technology, this episode is a must-listen guide to navigating the untamed wild west of AI. Support the show www.kulkarnilawfirm.com

• Transcript

Sponsoring Cannabis Research

Send us Fan Mail NOT LEGAL ADVICE For decades, cannabis research in the U.S. was stifled by Schedule I restrictions, requiring high-security vaults, mountains of paperwork, and extremely limited supply chains. With Executive Order 14370, the landscape has shifted. Marijuana is moving to Schedule III, and the rules of the game have officially changed. In this episode of KLF Deep Dive, attorney-pharmacist Darshan Kulkarni breaks down the practical impact of this reclassification for clinical trial sponsors. We move beyond the headlines to discuss the "pharmacy-style" compliance now required and the hidden pitfalls of using non-pharmacist staff at trial sites. Key Topics Covered: The Security Shift: Why you can ditch the steel vaults, but why your new "pharmacy" status brings a different set of DEA headaches. Supply Chain Normalization: Moving away from the "one-plant" monopoly toward a traditional pharma infrastructure. The Real-World Evidence (RWE) Invitation: How the FDA is encouraging the use of patient records and "real-world stories" to prove efficacy. The Compliance Trap: Why vetting your trial sites’ staffing—specifically the use of CRNAs vs. Pharmacists—is now a top-tier regulatory risk. Targeting Federal Grants: Why studies focusing on veterans and the elderly are currently "first in line" for federal support. The Bottom Line: The federal government has moved from stopping research to starting it. But as a sponsor, your site list just got bigger—and so did your responsibility to ensure they aren't just pretending to be compliant. Support the show: www.kulkarnilawfirm.com Support the show www.kulkarnilawfirm.com

• Transcript

The New Era of Personal Consent Decrees

Send us Fan Mail Is your career protected from your company’s mistakes? For decades, a Federal Consent Decree was a corporate headache. Today, it’s a personal professional death sentence. In this episode, Darshan Kulkarni breaks down the seismic shift in federal enforcement: why agencies are now naming CEOs, CMOs, and Heads of Clinical operations by name in injunctions. We explore the "Delegation Trap," the rise of the Office of Data Reliability, and the KLF Playbook for ensuring your name never appears on a federal blackball list. Support the show www.kulkarnilawfirm.com

• Transcript

Why Private Membership Associations Fail FDA Scrutiny

Send us Fan Mail In this episode of the KLF Deep Dive, Darshan Kulkarni deconstructs a persistent and dangerous myth circulating in life sciences and investment circles: the Private Membership Association (PMA). While often marketed as a "contract-based loophole" to evade FDA oversight and civil liability, the reality in federal court is starkly different. Darshan examines the constitutional limits of "freedom of association" and analyzes key case law—including Little v. Q Lasers—to demonstrate why PMAs are viewed by judges as red flags rather than legal shields. If you are advising clients on regulatory shortcuts, this is a must-listen briefing on maintaining professional integrity and statutory compliance. Support the show www.kulkarnilawfirm.com

• Transcript

The Hidden Reason Sites are Firing Recruiters

Send us Fan Mail What would happen if your clinical trial sites were suddenly banned from using you? In this episode, Darshan Kulkarni uncovers a hidden regulatory shift: state licensing boards are tightening the "Corporate Practice of Medicine" and "Fee Splitting" laws. If your recruitment fees are tied to enrollment or revenue, you aren't just a vendor—you’re a legal liability. We break down the MSO structures that are failing, the "Red Zones" in state law, and how KLF re-architects your contracts to make you the safest, most scalable partner in the life sciences industry. Support the show www.kulkarnilawfirm.com

• Transcript

Don’t Let Your PI Walk Away With Your Study

Send us Fan Mail In this tactical masterclass, Darshan Kulkarni breaks down the critical legal architecture required to protect clinical trial sites during rapid expansion. As PIs and Sub-Investigators move between organizations, the risk of losing proprietary data and patient continuity skyrockets. Learn the specific clauses—from non-solicitation to transition requirements—that ensure your site retains its value and your sponsors remain confident. Don't let your most valuable assets walk out the door; learn how to lock down your contracts today. Support the show www.kulkarnilawfirm.com

• Transcript

Safe or Just "Not Dirty"? The Regulatory Gamble of Compounded Drugs

Send us Fan Mail In this episode, Darshan Kulkarni breaks down the staggering legal difference between the branded drugs you know (like Mounjaro) and the compounded versions flooding the market. Using a brilliant "Coke vs. RC Cola" analogy, we explore why "clean vats" aren't the same as "proven science." If you are a patient, a provider, or a legal professional in the life sciences space, you need to understand the four pillars of FDA approval—and why some of the most popular drugs on the market today are legally allowed to skip the hardest parts Support the show www.kulkarnilawfirm.com

• Transcript